Representative examples of polypeptide fragments of the invention, include, for example, fragments comprising, or alternatively consisting of, from about amino acid number 1-20, 21-40, 41-60, 61-80, 81-100, 102-120, 121-140, 141-160, or 161 to the end of the coding region
wherein A250 is substituted with either a C, D, E, F, G, H, I, K, L, M, N, P, Q, R, S, T, V, W, or Y
Yang L, Takimoto T, Fujimoto J
Historia zacza si w latach 90
INOV2a, ACAGTTGTAAGGGATCTTGTGGCTGTCAGGATGGCAGAGGAGCAGGAGTTCACCCAGC jCG 105757-01 TCTGCAAGTTGCCTGCACAGCCCTCACACCCACACTGCGTGAACAACACCTACCGCAG DNA Sequence CGCACAGCACTCCCAGGCTCTGCTCCGAGGGCTGCTGGCTCTCCGGGACAGCGGAATC CTCTTCGATGTTGTGCTGGTGGTGGAGGGCAGACACATCGAGGCCCATCGCATCCTGC TGGCTGCGTCCTGCGATTACTTCAGGAGAGGAATGTTTGCTGGGGGATTGAAGGAGAT GGAACAGGAAGAGGTCCTGATCCACGGTGTGTCCTACAATGCTATGTGCCAAATCCTA CATTTCATATACACCTCCGAGCTGGAGCTCAGCCTGAGCAATGTACAAGAGACACTGG TGGCTGCCTGCCAGCTGCAGATCCCAGAAATTATCCATTTCTGCTGTGATTTCCTCAT GTCCTGGGTGGACGAAGAGAACATTCTCGATGTCTACCGGCTGGCAGAGCTGTTTGAC TTGAGCCGCCTGACTGAGCAACTGGACACCTATATCCTCAAAAACTTTGTGGCCTTCT CTCGGACTGACAAGTACCGCCAGCTTCCATTGGAGAAGGTCTACTCCCTCCTCAGCAG CAATCGCCTGGAGGTCTCCTGCGAGACCGAGGTATATGAGGGGGCCCTTCTCTACCAT TATAGCCTGGAGCAGGTGCAGGCTGACCAGATCTCGCTGCACGAGCCCCCAAAGCTCC TTGAGACAGTGCGGTTTCCGCTGATGGAAGCTGAGGTCCTGCAGCGGCTGCATGACAA GCTGGACCCCAGCCCTTTGAGGGACACAGTGGCCAGCGCCCTCATGTACCACCGGAAC GAGAGCCTACAGCCCAGCCTGCAGAGCCCGCAAACGGAGCTGCGGTCGGACTTCCAGT GCGTTGTGGGCTTCGGGGGCATTCACTCCACGCCGTCCACTGTCCTCAGCGACCAGGC CAAGTATCTAAACCCCTTACTGGGAGAGTGGAAGCACTTCACTGCCTCCCTGGCCCCC CGCATGTCCAACCAGGGCATCGCGGTGCTCAACAACTTCGTATACTTGATTGGAGGGG ACAACAATGTCCAAGGATTTCGAGCAGAGTCCCGATGCTGGAGGTATGACCCACGGCA CAACCGCTGGTTCCAGATCCAGTCCCTGCAGCAGGAGCACGCCGACCTGTCCGTGTGT GTTGTAGGCAGGTACATCTACGCTGTGGCGGGCCGTGACTACCACAATGACCTGAATG CTGTGGAGCGCTACGACCCTGCCACCAACTCCTGGGCATACGTGGCCCCACTCAAGAG GGAGGTAGTGTATGCCCACGCAGGCGCGACGCTGGAGGGGAAGATGTATATCACCTGC GGCCGCAGAGGGGAGGATTACCTGAAAGAGACACACTGCTACGATCCAGGCAGCAACA CTTGGCACACACTGGCTGATGGGCCTGTGCGGCGCGCCTGGCACGGCATGGCAACCCT CCTCAACAAGCTGTATGTGATCGGGGGCAGCAACAACGATGCCGGATACAGGAGGGAC GTGCACCAGCTCCCAGGTGCCCACGTGCTGCGCTGGCTGGAGGCAGCAAGGGGACGAG TGTGGGATTGCGGTGTGCGAAGGCAACTCCACGTGCTCAGAGAACGAGGTGTGCGTGA^ GGCCTGGCGAGTGCCGCTGCCGCCACGGCTACTTCGGTGCCAACTGCGACACCAGTGT GGCCAGTGCAAGGGGCCAGCAGCCGTGCACGGTGGCCGAGGGCCGCTGCTTGACGTGC GAGCCCGGCTGGAACGGAACCAAGTGCGACCAGCCTTGCGCCACCGGTTTCTATGGCG AGGGCTGCAGCCACCGCTGTCCGCCATGCCGCGACGGGCATGCCTGTAACCATGTCAC CGGCAAGTGTACGCGCTGCAACGCGGGCTGGATCGGCGACCGGTGCGAGACCAAGTGT AGCAATGGCACTTACGGCGAGGACTGCGCCTTCGTGTGCGCCGACTGCGGCAGCGGAC ACTGCGACTTCCAGTCGGGGCGCTGCCTGTGCAGCCCTGGCGTCCACGGGCCCCAGTG AGTGCCCCGGGACCGGGAGGGGGTTGGGGGCTTGTACCTGCCACAGAGGGGGGTCCAG CCGACGAGGTGGCCTCTCCACCCTGAGCTGGGTTATCACCTCAGCCTTGGTCCCTTAC CCCAGCTAGGGAGTGACAGTAGGCTCTTTGGGGGCAGTTTCCTGCCTGGATGTCGGGG jAGC'fCACGTTCAGCGCAGGATCTGGTGACCAGTCCAGCCTGTGTCAGTGGGCTCTTAA GGTGACCCCGAGTTGGTACAGAAGGACCAGGGACCTCCACTTACAGCCAAGGGTCTGG TTCAGCAGCCCCTCTTCCCACCTAGCCGAGTCAGCCCCAGCAGTGGGCGCTGCGGCGC GGCCACCACGGGTCCTATCCCCCAGGCCCCCCCACTAGTGTTGTGCAACATTCGTTTC CAAAACATCCACTACCCAATATGTGCC ORF Start: ATG at 31 ORF Stop: TAA at 1903 SEQ ID NO: 16 624 aa MWat 71369.7 Da lNOV2a, MAEEQEFTQLCKLPAQPSHPHCVNNTYRSAQHSQALLRGLLALRDSGILFDWLWEG JCG105757-01 RHIEAHRILLAASCDYFRRGMFAGGLKEMEQEEVLIHGVSYNA CQILHFIYTSELEL iProtein Sequence SLSNVQETLVAACQLQIPEIIHFCCDFLMS*WVDEENILDVYRLAELFDLSRLTEQLDT YILKNFVAFSRTDKYRQLPLEKVYSLLSSNRLEVSCETEVYEGALLYHYSLEQVQADQ ISLHEPPKLLETVRFPLMEAEVLQRLHDKLDPSPLRDTVASALMYHRNESLQPSLQSP QTELRSDFQCWGFGGIHSTPSTVLSDQAKYLNPLLGEWKHFTASLAPRMSNQGIAVL NNFVYLIGGDNNVQGFRAESRC RYDPRHNR FQIQSLQQEHADLSVCVVGRYIYAVA GRDYHNDLNAVERYDPATNSWAYVAPLKREWYAHAGATLEGKMYITCGRRGEDYLKE THCYDPGSNTWHTLADGPVRRAWHG ATLLNKLYVIGGSNNDAGYRRDVHQLPGAHVL R LEAARGRVDCGVRRQLHVLRERGVREA RVPLPPRLLRCQLRHQCGQCKGPAAVH GGRGPLLDVRARLERNQVRPALRHRFLWRGLQPPLSAMPRRACL Further analysis of the NOV2a protein yielded the following properties shown in Table 2B
B lymphocyte accumulations in human pulmonary sarcoidosis
